CAR-T Cell Therapy
High-quality starting material for one of the most promising therapies in modern oncology.
The Therapy
What is CAR-T cell therapy?
In CAR-T cell therapy, the patient's own T cells are genetically modified to specifically recognize and destroy cancer cells.
The chimeric antigen receptor (CAR) is introduced into the T cells using viral vectors. These modified cells are expanded and re-infused into the patient, where they attack tumor cells with specific surface markers. The therapy shows impressive results in various hematological diseases, including acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
Our Role
How CytoCare supports CAR-T therapy
The success of CAR-T therapy begins with the quality of the starting material. CytoCare provides the critical foundation: high-quality leukapheresis products with optimal T cell yield.
- Leukapheresis with high T cell purity and viability
- Flexible scheduling for time-critical treatments
- GMP-compliant processes for clinical applications
- Complete documentation and traceability
- Cryopreservation and temperature-controlled shipping